DiRocco Derek 4

What Happened
Derek DiRocco, a director of Acrivon Therapeutics (ACRV), was granted a derivative award on 2026-06-17 covering 20,275 shares (transaction code A). The grant shows $0 cash paid at grant (i.e., an option/award rather than an open‑market purchase or sale). The filing does not report a cash value realized at grant.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22 (filed five days after the transaction). This appears to be outside the usual two-business-day reporting window for Form 4 filings.
• Instrument and amount: Award/option for 20,275 shares; reported price $0.00 (derivative).
• Vesting: The option’s shares vest on the date immediately preceding the issuer’s next annual meeting of stockholders, subject to continuous service (per footnote).
• Beneficial ownership: DiRocco holds the option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P.; he is obligated to turn over net cash or stock received upon exercise to the adviser to offset advisory fees and disclaims beneficial ownership of the option and underlying common stock (per footnote).
• Shares owned after transaction: Not specified in the filing.

Context
This is a derivative award (an option grant) to a director, not an open‑market purchase or sale. Because DiRocco disclaims beneficial ownership and holds the option for RA Capital funds, the economic interest appears to be institutional rather than a personal investment by the director. Such awards are common for compensation/arrangement purposes and do not by themselves indicate personal trading sentiment.